Jump to main content
Jump to site search
SCHEDULED MAINTENANCE Close the message box

Maintenance work is planned for Monday 16 August 2021 from 07:00 to 23:59 (BST).

Website performance may be temporarily affected and you may not be able to access some PDFs or images. If this does happen, refreshing your web browser should resolve the issue. We apologise for any inconvenience this might cause and thank you for your patience.

All chapters


Hsp90 Inhibitors in Clinic

Hsp90 has been extensively studied as a viable oncogenic target since 1985, when it was first shown that targeting Hsp90 results in anti-neoplastic effects. Early clinical development was hindered by the fact that both geldanamycin and radicicol, the first biologically occurring compounds shown to inhibit Hsp90, were too toxic for use in the clinic. This limitation was overcome by the development of the first-generation geldanamycin-based compounds, which entered into clinic in 2003. Although, these first-generation compounds showed clinical limitation of use due to hepatotoxicity, development of newer Hsp90 inhibitors have shown early promise. Herein we will review the current landscape of Hsp90 inhibitors.

Publication details

Print publication date
30 Oct 2013
Copyright year
Print ISBN
From the book series:
Drug Discovery